EYPT vs CAPR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CAPR Captures Institutional Edge (3โ1 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Capricor Therapeutics Inc (CAPR) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while EYPT counters with relative strength in Valuation. Fundamentally, EYPT trades at 6.2x Forward P/E with -11369.3% operating margin (-90.5% YoY revenue) versus CAPR at 78.7x Forward P/E and 0.0% operating margin (-7.9% YoY). In options structure, EYPT sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro) against CAPR sits in CONSOLIDATION (89th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EYPT Revenue | CAPR Revenue | EYPT Op. Margin | CAPR Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $0M | -853.6% | -917.0% | EYPT |
| FY2019 | $20M | $0M | -235.0% | -769.5% | EYPT |
| FY2020 | $30M | $0M | -108.3% | -4412.6% | EYPT |
| FY2021 | $40M | $0M | -149.6% | -8549.9% | EYPT |
| FY2022 | $40M | $0M | -240.6% | -1163.9% | EYPT |
| FY2023 | $50M | $30M | -163.1% | -95.6% | CAPR |
| FY2024 | $40M | $20M | -337.1% | -191.1% | CAPR |
| FY2025 | $30M | N/A | -776.0% | N/A | EYPT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EYPT | CAPR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $26.8M | $595.4M | Larger Scale | CAPR |
| Trailing P/E Ratio Valuation | 6.2x | 78.7x | Lower Multiple | EYPT |
| Forward P/E Ratio Valuation | 6.2x | 78.7x | Lower Multiple | EYPT |
| Revenue Growth (YoY) Growth | -90.5% | -7.9% | Higher Growth | CAPR |
| Operating Margin (TTM) Profitability | -11369.3% | 0.0% | Higher Margin | CAPR |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -148.7% | -100.5% | Higher ROE | CAPR |
| 52-Week Range Position Momentum | 0% ($0โ$19) | 15% ($3โ$40) | Stronger Trend | CAPR |
| Beta / 30D Volatility Risk Regime | 1.43ฮฒ ยท 104% Vol | 1.52ฮฒ ยท 152% Vol | Lower Realized Risk | EYPT |
| Unified Institutional Score Composite Signal | 43.5 / 100 (HOLD) | 28.0 / 100 (SELL) | Higher Composite | EYPT |